Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 14/20 | 0.58 |
| ▸ | ALK | Q9UM73 | 5/20 | 0.53 |
| ▸ | MET | P08581 | 1/20 | 0.53 |
| ▸ | INSR | P06213 | 3/20 | 0.52 |
| ▸ | IGF1R | P08069 | 2/20 | 0.52 |
| ▸ | ZAP70 | P43403 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27075983 | 1.00 | EGFR (0.58) | EGFRALKMETINSRIGF1R | |
| SCHEMBL24993148 | 0.94 | EGFR (0.61) | EGFRALKMETINSRIGF1R | |
| SCHEMBL27075981 | 0.91 | EGFR (0.55) | EGFRALKMETINSRIGF1R | |
| SCHEMBL24992306 | 0.90 | EGFR (0.54) | EGFRALKMETINSRIGF1R | |
| SCHEMBL30015407 | 0.89 | EGFR (0.55) | EGFRALKINSRIGF1RZAP70 | |
| SCHEMBL27076050 | 0.89 | EGFR (0.55) | EGFRALKINSRIGF1RZAP70 | |
| SCHEMBL24992297 | 0.89 | EGFR (0.57) | EGFRALKMETINSRIGF1R | |
| SCHEMBL27075954 | 0.88 | EGFR (0.66) | EGFRALKMETINSRIGF1R | |
| SCHEMBL24992455 | 0.87 | EGFR (0.69) | EGFRMET | |
| SCHEMBL30014786 | 0.87 | EGFR (0.69) | EGFRMET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12297194-B2 | N2-phenylpyrimidine-2,4-diamine compounds, and preparation methods and methods of use thereof | Bridge Biotherapeutics, Inc. (KR) | 2025-05-13 | — | — | US | disclosed |
| US-20220332711-A1 | N2-PHENYLPYRIMIDINE-2,4-DIAMINE COMPOUNDS, AND PREPARATION METHODS AND METHODS OF USE THEREOF | Bridge Biotherapeutics, Inc. (KR) | 2022-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12297194-B2 | N2-phenylpyrimidine-2,4-diamine compounds, and preparation methods and methods of use thereof | EGFR, ERBB2, ERBB4 | EGFR 1/4885ALK 90/4885MET 299/4885 |
| US-20220332711-A1 | N2-PHENYLPYRIMIDINE-2,4-DIAMINE COMPOUNDS, AND PREPARATION METHODS AND METHODS OF USE THEREOF | EGFR, ERBB2, ERBB4 | EGFR 1/4885ALK 90/4885MET 299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.